Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, November 10, 2023
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
Rachel Vatnsdal Maintained (ADPT) at Buy with Decreased Target to $11 on, Nov 10th, 2023
Rachel Vatnsdal of JP Morgan, Maintained "Adaptive Biotechnologies Corporation" (ADPT) at Buy with Decreased Target from $12 to $11 on, Nov 10th, 2023.
Rachel has made no other calls on ADPT in the last 4 months.
There are 2 other peers that have a rating on ADPT. Out of the 2 peers that are also analyzing ADPT, 1 agrees with Rachel's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Tejas Savant of "Morgan Stanley" Maintained at Hold with Decreased Target to $10 on, Tuesday, October 24th, 2023
This is the rating of the analyst that currently disagrees with Rachel
- David Westenberg of "Piper Sandler" Maintained at Buy with Decreased Target to $13 on, Monday, October 16th, 2023
